Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression.

IF 2.2 3区医学 Q3 PERIPHERAL VASCULAR DISEASE Current Opinion in Nephrology and Hypertension Pub Date : 2024-05-01 Epub Date: 2024-02-23 DOI:10.1097/MNH.0000000000000976

Michael W Holliday, Livia Frost, Sankar D Navaneethan

{"title":"Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression.","authors":"Michael W Holliday, Livia Frost, Sankar D Navaneethan","doi":"10.1097/MNH.0000000000000976","DOIUrl":null,"url":null,"abstract":"Purpose of review: Diabetic kidney disease continues to increase, and several novel therapeutic agents have been shown to slow the progression of chronic kidney disease in those with diabetes. This review summarizes more recent data on the role of glucagon-like peptide-1 (GLP-1) receptor agonists and kidney outcomes.Recent findings: Posthoc analysis of cardiovascular outcome trials, as well as several retrospective studies, demonstrate benefits of GLP-1 receptor agonist therapy for chronic kidney disease progression in diabetics. Although limited randomized clinical trials evidence assessing the effects of GLP-1 receptor agonists on kidney outcomes in diabetic chronic kidney disease patients have been published, FLOW-CKD trial was halted based on interim data for efficacy, and results are awaited.Summary: GLP-1 receptor agonism is a promising therapy for slowing the progression of diabetic chronic kidney disease. Recent studies support kidney benefits GLP-1 receptor agonists over insulin and dipeptidyl peptidase-4-inhibitors, and the FLOW-CKD trial would inform the potential benefits for reducing the need for dialysis and kidney-disease related mortality in those with kidney disease.","PeriodicalId":10960,"journal":{"name":"Current Opinion in Nephrology and Hypertension","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11126299/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Nephrology and Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MNH.0000000000000976","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Diabetic kidney disease continues to increase, and several novel therapeutic agents have been shown to slow the progression of chronic kidney disease in those with diabetes. This review summarizes more recent data on the role of glucagon-like peptide-1 (GLP-1) receptor agonists and kidney outcomes.

Recent findings: Posthoc analysis of cardiovascular outcome trials, as well as several retrospective studies, demonstrate benefits of GLP-1 receptor agonist therapy for chronic kidney disease progression in diabetics. Although limited randomized clinical trials evidence assessing the effects of GLP-1 receptor agonists on kidney outcomes in diabetic chronic kidney disease patients have been published, FLOW-CKD trial was halted based on interim data for efficacy, and results are awaited.

Summary: GLP-1 receptor agonism is a promising therapy for slowing the progression of diabetic chronic kidney disease. Recent studies support kidney benefits GLP-1 receptor agonists over insulin and dipeptidyl peptidase-4-inhibitors, and the FLOW-CKD trial would inform the potential benefits for reducing the need for dialysis and kidney-disease related mortality in those with kidney disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胰高血糖素样肽-1 激动剂在减缓慢性肾病进展方面的新证据。

综述的目的：糖尿病肾病的发病率持续上升，一些新型治疗药物已被证明可减缓糖尿病患者慢性肾病的进展。本综述总结了有关胰高血糖素样肽-1（GLP-1）受体激动剂的作用和肾脏预后的最新数据：最近的研究结果：对心血管预后试验的事后分析以及几项回顾性研究表明，GLP-1 受体激动剂治疗对糖尿病患者慢性肾病的进展有益。虽然评估 GLP-1 受体激动剂对糖尿病慢性肾脏病患者肾脏预后影响的随机临床试验证据有限，但 FLOW-CKD 试验因中期疗效数据而停止，目前仍在等待结果。摘要：GLP-1 受体激动剂是一种很有希望减缓糖尿病慢性肾脏病进展的疗法。最近的研究支持 GLP-1 受体激动剂比胰岛素和二肽基肽酶-4 抑制剂更有益于肾脏，FLOW-CKD 试验将为减少肾病患者的透析需求和肾病相关死亡率提供潜在的益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Opinion in Nephrology and Hypertension 医学-泌尿学与肾脏学

CiteScore

5.70

自引率

6.20%

发文量

132

审稿时长

6-12 weeks

期刊介绍： A reader-friendly resource, Current Opinion in Nephrology and Hypertension provides an up-to-date account of the most important advances in the field of nephrology and hypertension. Each issue contains either two or three sections delivering a diverse and comprehensive coverage of all the key issues, including pathophysiology of hypertension, circulation and hemodynamics, and clinical nephrology. Current Opinion in Nephrology and Hypertension is an indispensable journal for the busy clinician, researcher or student.